13258-63-4

Basic information

• Product Name: 4-(2-Aminoethyl)pyridine
• Synonyms: 2-(4-Pyridinyl)ethylamine;2-(4-Pyridyl)ethanamine;2-(Pyridine-4-yl)ethanamine;4-Pyridylethylamine;NSC 194298;4-(2-Aminoethyl)pyridine ,95%;Pyridine-4-ethanamine;4-Pyridineethylamine
• CAS NO: 13258-63-4
• Molecular Formula: C₇H₁₀N₂
• Molecular Weight: 122.17
• Product Categories: pharmacetical;Aminomethyl's;Pyridines;pyridine;C7 and C8;Heterocyclic Building Blocks
• Mol File: 13258-63-4.mol
• Article Data: 11

Chemical Properties

• Melting Point: 115-116 °C
• Boiling Point: 104 °C9 mm Hg(lit.)
• Flash Point: >230 °F
• Appearance: /
• Density: 1.0238 g/mL at 25 °C(lit.)
• Vapor Pressure: 0.065mmHg at 25°C
• Refractive Index: n20/D 1.5380(lit.)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.07±0.10(Predicted)
• Sensitive: Air Sensitive
• CAS DataBase Reference: 4-(2-Aminoethyl)pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-Aminoethyl)pyridine(13258-63-4)
• EPA Substance Registry System: 4-(2-Aminoethyl)pyridine(13258-63-4)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-37/39
• RIDADR: 2735
• WGK Germany: 3
• TSCA: Yes
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 13258-63-4(Hazardous Substances Data)

Usage

General Description

4-(2-Aminoethyl)pyridine is an organic chemical compound with the formula C7H10N2. 4-(2-Aminoethyl)pyridine is characterized by a pyridine ring, which is a six-atom aromatic ring with five carbon atoms and one nitrogen atom, and an attached 2-aminoethyl group. It has a molecular weight of 122.17 g/mol. As a base compound, it reacts with acids to form salts. The compound exhibits properties common to both amines and pyridines. While it is stable under general conditions, it is advised to avoid strong oxidants as it can react in hazardous ways. Functional applications of 4-(2-Aminoethyl)pyridine include versatile roles in organic synthesis and components of some pharmaceuticals.

InChI:InChI=1/C7H10N2/c8-4-1-7-2-5-9-6-3-7/h2-3,5-6H,1,4,8H2/p+1

Upstream product

• 100-43-6 4-vinylpyridine 
• 631-61-8 ammonium acetate 
• 75140-34-0 2-amino-1-[4]pyridyl-ethanone 
• 92521-18-1 2-amino-1-[4]pyridyl-ethanol 
• 855184-51-9 (2-[4]pyridyl-ethyl)-carbamic acid methyl ester 
• 86423-55-4 diethyl N-[2-(pyridin-4-yl)-ethyl]-phosphoramidate 
• 39640-62-5 2-(pyridine-4-yl)-acetamide 
• 13121-99-8 pyridin-4-ylacetonitrile 
• 67-56-1 methanol 
• 7732-18-5 water 
• 872-85-5 pyridine-4-carbaldehyde 
• 86423-54-3 Diethyl N-[β-(pyridin-4-yl)-vinyl]-phosphoramidate 
• 86052-61-1 ({[1-Pyridin-4-yl-meth-(E)-ylidene]-amino}-methyl)-phosphonic acid diethyl ester 
• 84200-07-7 3-(pyridin-4-yl)-propionamide 

Downstream Products

• 63825-04-7 3,4,5-trimethoxy-benzoic acid-(2-[4]pyridyl-ethylamide) 
• 107774-78-7 N-(2-[4]pyridyl-ethyl)-benzamide 
• 101938-75-4 N-(2-[4]pyridyl-ethyl)-toluene-4-sulfonamide 
• 126007-87-2 2-<4-<3-<<2-(4-pyridyl)ethyl>amino>-2-hydroxypropoxy>phenyl>-4-(2-thienyl)imidazole hemihydrate 
• 308242-50-4 3-[7-chloro-5-(2-fluoro-phenyl)-2-(2-pyridin-4-yl-ethylamino)-3H-benzo[e][1,4]diazepin-3-yl]-propionic acid methyl ester 
• 681161-17-1 N-[2-(pyridin-4-yl)ethyl]isonicotinamide 
• 696603-76-6 2-(2,4-dichloro-phenylamino)-N-(2-pyridin-4-yl-ethyl)-2-o-tolyl-acetamide 
• 696601-64-6 2-(2-bromo-phenyl)-2-(2-chloro-4-methyl-phenylamino)-N-(2-pyridin-4-yl-ethyl)-acetamide 

Relevant articles and documents

-

-

Structure-based evolution of subtype-selective neurotensin receptor ligands

Subtype-selective agonists of the neurotensin receptor NTS2 represent a promising option for the treatment of neuropathic pain, as NTS2 is involved in the mediation of m-opioid-independent anti-nociceptive effects. Based on the crystal structure of the subtype NTS1 and previous structure-activity relationships (SARs) indicating a potential role for the sub-pocket around Tyr11 of NT(8-13) in subtype-specific ligand recognition, we have developed new NTS2-selective ligands. Starting from NT(8-13), we replaced the tyrosine unit by β2-amino acids (type 1), by heterocyclic tyrosine bioisosteres (type 2) and peptoid analogues (type 3). We were able to evolve an asymmetric synthesis of a 5-substituted azaindolylalanine and its application as a bioisostere of tyrosine capable of enhancing NTS2 selectivity. The S-configured test compound 2a, [(S)-3-(pyrazolo[1,5-α]pyridine-5-yl)-propionyl11]NT(8-13), exhibits substantial NTS2 affinity (4.8 nm) and has a nearly 30-fold NTS2 selectivity over NTS1. The (R)-epimer 2b showed lower NTS2 affinity but more than 600-fold selectivity over NTS1.

SPIROHYDANTOIN COMPOUNDS AND THEIR USE AS SELECTIVE ANDROGEN RECEPTOR MODULATORS

The present invention relates to a compound of formula (1-1 ) in free form or in pharmaceutically acceptable salt form in which the substituents are as defined in the specification; to its preparation, to its use as a medicament and to medicaments comprising it. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase

Matriptase is an epithelium-derived type II transmembrane serine protease and has been implicated in the activation of substrates such as pro-HGF/SF and pro-uPA, which are likely involved in tumor progression and metastasis. Through screening, we have identified bis-basic secondary amides of sulfonylated 3-amidinophenylalanine as matriptase inhibitors. X-ray analyses of analogues 8 and 31 in complex with matriptase revealed that these inhibitors occupy, in addition to part of the previously described S4-binding site, the cleft formed by the molecular surface and the unique 60 loop of matriptase. Therefore, optimization of the inhibitors included the incorporation of appropriate sulfonyl substituents that could improve binding of these inhibitors into both characteristic matriptase subsites. The most potent derivatives inhibit matriptase highly selective with Ki values below 5 nM. Molecular modeling revealed that their improved affinity results from interaction with the S4 site of matriptase. Analogues 8 and 59 were studied in an orthotopic xenograft mouse model of prostate cancer. Compared to control, both inhibitors reduced tumor growth, as well as tumor dissemination.